The Association of Pharmaceutical Industry discusses counterfeit medicines
Source: actasanitaria.com
On March 14, the 39th Symposium of the Spanish Association of Pharmaceutical Industry (AEFI) began in Barcelona, ??under the theme ‘Tracings and in contact with new challenges’, a meeting that will be attended by close 350 representatives of the different health administrations and industry, to discuss issues such as counterfeit medicines and novelties in medical devices and clinical trials. During the opening of this symposium, which is celebrated until March 15, the president of the same , Núria Ortoll, pointed out that “currently, we are in a technologically advanced society with multiple forums to share information in a virtual way, but it is the personal and direct contact between people in this type of events that drives debates with a fruitful exchange of experiences , ideas and concerns. The aim of the Symposium is to contribute to the training, updating and innovation of knowledge of the professional working in the industry. “‘Strategies for the design of new antibiotics’ was the title of the inaugural lecture given by the head of the Hospital Microbiology Service Clinician of Barcelona, ??Dr. Jordi Vila, with whom this edition starts, in which AEFI focused on the most current issues in the biopharmaceutical field. Thus, one of the first tables was focused on the Brexit countdown, achievements and open key issues to comply with European legislation. Also, a table was organized on the first experiences with the serialization and verification of medicines, after the incorporation of the safety devices in medicines of the European Union (EU), mandatory since February 2019.New regulations of health products. This past year, the European Medicines Agency (EMA) and the Spanish Agency for Medicines and Health Products (AEMPS) have been publishing documents to facilitate the interpretation of the regulations, which sought to be helpful for the agents involved. symposium will address the new regulations for medical devices as a result of the legislative change on medical devices and in vitro diagnostics that replace the three European directives. These new regulations aim to establish a solid and transparent regulatory framework that ensures a high level of health and safety protection while supporting innovation. In this edition, the new features of the System will also be announced. Spanish Cosmetovigilance described in the Royal Decree that regulates cosmetic products and in which, among other aspects, establishes the Spanish Cosmetovigilance System and the notification system to the national competent authorities that was published in February 2018.
At Distefar we support those advances that suppose the improvement and security of the medicines
